Affimed to Present at the Oppenheimer 27th Annual
Post# of 301275
Heidelberg, Germany, March 14, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 4:30 a.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php . A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com .
IR Contact:
Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: a.alexandru@affimed.com
(0)
(0)